BioCryst Pharmaceuticals (NASDAQ:BCRX) CFO Thomas R. Staab II unloaded 10,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $13.58, for a total transaction of $135,800.00. Following the completion of the transaction, the chief financial officer now directly owns 162,942 shares in the company, valued at approximately $2,212,752. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) belongs to Healthcare sector. Its weekly performance is 20.08%. On last trading day company shares ended up $12.80. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) distance from 50-day simple moving average (SMA50) is 3.90%.
Investment analysts at Wedbush initiated coverage on shares of Mirati Therapeutics (NASDAQ:MRTX) in a report released on Thursday. The firm set an “outperform” rating and a $29.00 price target on the stock. Wedbush’s target price indicates a potential upside of 54.50% from the company’s current price. Mirati Therapeutics, Inc. (NASDAQ:MRTX) shares increased 2.26% in last trading session and ended the day at $18.99. MRTX return on assets is -138.60%. Mirati Therapeutics, Inc. (NASDAQ:MRTX) quarterly performance is 7.23%.
Announced on Sep 11, that Eastman Chemical Co. (NYSE:EMN) agreed on Thursday to buy the Taminco Corporation, a maker of specialized chemicals, for $1.7 billion in cash, becoming the third owner of the company in the last three years. On 03 October, Eastman Chemical Co. (NYSE:EMN) shares increased 0.43% and was closed at $78.91. EMN EPS growth in last 5 year was 26.80%. Eastman Chemical Co. (NYSE:EMN) year to date (YTD) performance is -1.03%.
On Sept. 25, Securities lawyers at Dunnam & Dunnam are investigating the board of Pike Corporation (NYSE MKT:PIKE) in connection with the sale of Pike to Court Square Capital Partners. Pike Corporation (NYSE:PIKE) ended the last trading day at $11.88. Company weekly volatility is calculated as 0.66% and price to cash ratio as 379.45. Pike Corporation (NYSE:PIKE) showed a weekly performance of -0.59%.
General Motors Company (NYSE:GM)’s recall problem continues to haunt the company. The automaker on Friday announced two new recalls totaling about 524,400 vehicles in North America. GM is recalling 430,550 Cadillac SRX and Saab 9-4X SUVs, and 89,294 Chevrolet Sparks. General Motors Company (NYSE:GM) belongs to Consumer Goods sector. Its net profit margin is 3.10% and weekly performance is 1.78%. On last trading day company shares ended up $33.76. General Motors Company (NYSE:GM) distance from 50-day simple moving average (SMA50) is 0.17%.